Table 4. Subgroup analysis of the prognostic significance of soluble MICA/B.
| Number of studies | Number of patients | HR 95%CI | Overall effectP-value | Subgroup differences P-value | I2 | |
|---|---|---|---|---|---|---|
| Cancer type | 0.47 | |||||
| Melanoma | 5 | 628 | 1.52 (1.23–1.88) | < 0.0001 | 49% | |
| OSCC | 2 | 173 | 2.65 (1.02–6.84) | 0.04 | 0% | |
| Digestive system cancers | 5 | 377 | 1.70 (1.35–2.13) | < 0.00001 | 58% | |
| ELISA | 0.09 | |||||
| sMICA | 11 | 1297 | 1.60 (1.37–1.87) | < 0.00001 | 47% | |
| sMICB | 2 | 185 | 2.86 (1.49–5.51) | 0.002 | 0% | |
| Multivariate correction | 0.48 | |||||
| Yes | 7 | 736 | 1.59 (1.32–1.92) | < 0.00001 | 58% | |
| No | 6 | 746 | 1.78 (1.38–2.28) | < 0.00001 | 28% | |
| Sample size | 5 | 0.79 | ||||
| ≤ 100 | 5 | 342 | 1.70 (1.33–2.17) | < 0.0001 | 44% | |
| > 100 | 8 | 1140 | 1.63 (1.34–1.97) | < 0.00001 | 52% |